Rare nasal cancer under the microscope: new study aims to unlock secrets
NCT ID NCT04755205
First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 16 times
Summary
This study is following children and adults with olfactory neuroblastoma, a rare cancer of the nasal cavity, to learn more about how the disease behaves over time. Researchers will collect medical records, blood samples, and survey responses from 525 participants to track symptoms, treatment responses, and outcomes. The goal is to better understand the disease and pave the way for improved treatments and supportive care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide crucial insights into how olfactory neuroblastoma progresses and responds to treatments, guiding better care strategies.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may take years and might not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 525 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2022
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with olfactory neuroblastoma.
- Ages
-
3 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA:. * Subjects with histologically documented olfactory neuroblastoma. * Age \>= 3 years old. * Ability of subject to understand and the willingness to sign a written consent document EXCLUSION CRITERIA: Pregnant women are excluded from this study because of more than minimal risk activities (imaging studies with contrast, biopsies) pertaining to enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esthesioneuroblastoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- Promising combo targets Hard-to-Treat childhood cancers
- New brain scan could spot tumors missed by standard MRI
- New radiation drug targets Hard-to-Treat cancers
- New radioactive drug combo takes aim at returning head and neck cancers
- Targeted pill takes on rare skull base cancers